Molecular basis and management of gastrointestinal stromal tumors

Ulas D. Bayraktar, Soley Bayraktar, Caio M. Rocha-Lima

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates various signaling pathways. Imatinib and sunitinib, both tyrosine kinase inhibitors directed to KIT, were approved for first- and secondline treatment of metastatic and unresectable GISTs. In this article, we will review the molecular pathogenesis of GISTs followed by a discussion of imatinib and sunitinib's role in the treatment of GISTs. Finally, we will introduce novel therapeutic options for imatinib- and sunitinib-resistant GISTs.

Original languageEnglish (US)
Pages (from-to)2726-2734
Number of pages9
JournalWorld Journal of Gastroenterology
Issue number22
StatePublished - Jun 2010


  • Gastrointestinal stromal tumor
  • Imatinib
  • KIT
  • Nilotinib
  • Sunitinib

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Molecular basis and management of gastrointestinal stromal tumors'. Together they form a unique fingerprint.

Cite this